Catriona John Waitt1, Paul Garner2, Laura Jayne Bonnett3, Saye Hock Khoo4, Laura Jayne Else4. 1. Department of Molecular and Clinical Pharmacology, University of Liverpool, Block A, The Waterhouse Buildings, 1-5 Brownlow Street, Liverpool L69 3GE, UK cwaitt@liv.ac.uk. 2. Clinical Sciences Department, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK. 3. Department of Biostatistics, University of Liverpool, Faculty of Health and Life Sciences, 1st Floor Duncan Building, Daulby Street, Liverpool L69 3GA, UK Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, 8 West Derby Street, Liverpool L69 7BE, UK. 4. Department of Molecular and Clinical Pharmacology, University of Liverpool, Block A, The Waterhouse Buildings, 1-5 Brownlow Street, Liverpool L69 3GE, UK.
Abstract
OBJECTIVES: The objectives of this study were to summarize antiretroviral drug concentrations in breast milk (BM) and exposure of breast-fed infants. METHODS: This was a systematic review of pharmacokinetic studies of HIV-positive women taking antiretrovirals that measured drugs in BM. The quality of pharmacokinetic and laboratory methods was assessed using pre-defined criteria. Pooled ratios and 95% CIs were calculated using the generalized inverse variance method and heterogeneity was estimated by the I(2) statistic. PubMed Central, SCOPUS and LactMed databases were searched. No date or language restrictions were applied. Searches were conducted up to 10 November 2014. Clinical relevance was estimated by comparing ingested dose with the recommended therapeutic dose for each drug. RESULTS: Twenty-four studies were included. There was substantial variability in the clinical and laboratory methods used and in reported results. Relative to maternal plasma (MP), NRTIs accumulate in BM, with BM : MP ratios (95% CI estimates) from 0.89 to 1.21 (14 studies, 1159 paired BM and MP samples). NNRTI estimates were from 0.71 to 0.94 (17 studies, 965 paired samples) and PI estimates were from 0.17 to 0.21 (8 studies, 477 paired samples). Relative to the recommended paediatric doses, a breast-fed infant may ingest 8.4% (95% CI 1.9-15.0), 12.5% (95% CI 2.6-22.3) and 1.1% (95% CI 0-3.6) of lamivudine, nevirapine and efavirenz, respectively, via BM. CONCLUSIONS: Transfer to untreated infants appears quantitatively important for some NRTIs and NNRTIs. The pharmacokinetic methods varied widely and we propose standards for the design, analysis and reporting of future pharmacokinetic studies of drug transfer during breastfeeding.
OBJECTIVES: The objectives of this study were to summarize antiretroviral drug concentrations in breast milk (BM) and exposure of breast-fed infants. METHODS: This was a systematic review of pharmacokinetic studies of HIV-positive women taking antiretrovirals that measured drugs in BM. The quality of pharmacokinetic and laboratory methods was assessed using pre-defined criteria. Pooled ratios and 95% CIs were calculated using the generalized inverse variance method and heterogeneity was estimated by the I(2) statistic. PubMed Central, SCOPUS and LactMed databases were searched. No date or language restrictions were applied. Searches were conducted up to 10 November 2014. Clinical relevance was estimated by comparing ingested dose with the recommended therapeutic dose for each drug. RESULTS: Twenty-four studies were included. There was substantial variability in the clinical and laboratory methods used and in reported results. Relative to maternal plasma (MP), NRTIs accumulate in BM, with BM : MP ratios (95% CI estimates) from 0.89 to 1.21 (14 studies, 1159 paired BM and MP samples). NNRTI estimates were from 0.71 to 0.94 (17 studies, 965 paired samples) and PI estimates were from 0.17 to 0.21 (8 studies, 477 paired samples). Relative to the recommended paediatric doses, a breast-fed infant may ingest 8.4% (95% CI 1.9-15.0), 12.5% (95% CI 2.6-22.3) and 1.1% (95% CI 0-3.6) of lamivudine, nevirapine and efavirenz, respectively, via BM. CONCLUSIONS: Transfer to untreated infants appears quantitatively important for some NRTIs and NNRTIs. The pharmacokinetic methods varied widely and we propose standards for the design, analysis and reporting of future pharmacokinetic studies of drug transfer during breastfeeding.
Authors: C V Fletcher; S P Kawle; T N Kakuda; P L Anderson; D Weller; L R Bushman; R C Brundage; R P Remmel Journal: AIDS Date: 2000-09-29 Impact factor: 4.177
Authors: J A Coates; N Cammack; H J Jenkinson; A J Jowett; M I Jowett; B A Pearson; C R Penn; P L Rouse; K C Viner; J M Cameron Journal: Antimicrob Agents Chemother Date: 1992-04 Impact factor: 5.191
Authors: Mark Mirochnick; Timothy Thomas; Edmund Capparelli; Clement Zeh; Diane Holland; Rose Masaba; Prisca Odhiambo; Mary Glenn Fowler; Paul J Weidle; Michael C Thigpen Journal: Antimicrob Agents Chemother Date: 2008-12-29 Impact factor: 5.191
Authors: Naser L Rezk; Nicole White; Arlene S Bridges; Mohamed F Abdel-Megeed; Tarek M Mohamed; Said S Moselhy; Angela D M Kashuba Journal: Ther Drug Monit Date: 2008-10 Impact factor: 3.681
Authors: Kirsten A Veldsman; Jean Maritz; Shahieda Isaacs; Mary G Katusiime; Anita Janse van Rensburg; Barbara Laughton; John W Mellors; Mark F Cotton; Gert U van Zyl Journal: AIDS Date: 2018-03-13 Impact factor: 4.177
Authors: Ahizechukwu C Eke; Adeniyi Olagunju; Jeremiah Momper; Martina Penazzato; Elaine J Abrams; Brookie M Best; Edmund V Capparelli; Adrie Bekker; Yodit Belew; Jennifer J Kiser; Kimberly Struble; Graham Taylor; Catriona Waitt; Mark Mirochnick; Tim R Cressey; Angela Colbers Journal: Clin Pharmacol Ther Date: 2020-10-15 Impact factor: 6.875
Authors: Kenneth K Mugwanya; Craig W Hendrix; Nelly R Mugo; Mark Marzinke; Elly T Katabira; Kenneth Ngure; Nulu B Semiyaga; Grace John-Stewart; Timothy R Muwonge; Gabriel Muthuri; Andy Stergachis; Connie L Celum; Jared M Baeten Journal: PLoS Med Date: 2016-09-27 Impact factor: 11.069